Cognitive Impairment in Parkinson's Disease: Epidemiology, Clinical Profile, Protective and Risk Factors
- PMID: 34068064
- PMCID: PMC8152515
- DOI: 10.3390/bs11050074
Cognitive Impairment in Parkinson's Disease: Epidemiology, Clinical Profile, Protective and Risk Factors
Abstract
Cognitive impairment is a common non-motor symptom in Parkinson's Disease (PD) and an important source of patient disability and caregiver burden. The timing, profile and rate of cognitive decline varies widely among individuals with PD and can range from normal cognition to mild cognitive impairment (PD-MCI) and dementia (PDD). Beta-amyloid and tau brain accumulation, oxidative stress and neuroinflammation are reported risk factors for cognitive impairment. Traumatic brain injury and pesticide and tobacco exposure have also been described. Genetic risk factors including genes such as COMT, APOE, MAPT and BDNF may also play a role. Less is known about protective factors, although the Mediterranean diet and exercise may fall in this category. Nonetheless, there is conflicting evidence for most of the factors that have been studied. The use of inconsistent criteria and lack of comprehensive assessment in many studies are important methodological issues. Timing of exposure also plays a crucial role, although identification of the correct time window has been historically difficult in PD. Our understanding of the mechanism behind these factors, as well as the interactions between gene and environment as determinants of disease phenotype and the identification of modifiable risk factors will be paramount, as this will allow for potential interventions even in established PD.
Keywords: Parkinson’s disease; clinical profile; dementia; mild cognitive impairment; risk factors.
Conflict of interest statement
P.G.L and E.B. declare no conflict of interest. I.L. research is supported by the National Institutes of Health grants: 2R01AG038791-06A, U01NS090259, U01NS100610, U01NS80818, R25NS098999, P20GM109025; U19 AG063911-1 and 1R21NS114764-01A1; the Michael J Fox Foundation, Parkinson Foundation, Lewy Body Association, Roche, Abbvie, Biogen, Centogene. EIP-Pharma, and Biohaven Pharmaceuticals. She was a member of the Scientific Advisory Board of Lundbeck and is a Scientific advisor for Amydis. She receives her salary from the University of California San Diego and as Chief Editor of
Figures

Similar articles
-
Incidence of Mild Cognitive Impairment and Dementia in Parkinson's Disease: The Parkinson's Disease Cognitive Impairment Study.Front Aging Neurosci. 2019 Feb 8;11:21. doi: 10.3389/fnagi.2019.00021. eCollection 2019. Front Aging Neurosci. 2019. PMID: 30800065 Free PMC article.
-
Mild cognitive impairment in Parkinson's disease and its progression onto dementia: a 16-year outcome evaluation of the Denbighshire cohort.Int J Geriatr Psychiatry. 2015 Oct;30(10):1048-55. doi: 10.1002/gps.4261. Epub 2015 Feb 11. Int J Geriatr Psychiatry. 2015. PMID: 25676160
-
Apolipoprotein Eε4: A Biomarker for Executive Dysfunction among Parkinson's Disease Patients with Mild Cognitive Impairment.Front Neurosci. 2017 Dec 20;11:712. doi: 10.3389/fnins.2017.00712. eCollection 2017. Front Neurosci. 2017. PMID: 29326545 Free PMC article.
-
Parkinson's disease dementia: Diagnostic criteria and risk factor review.J Clin Exp Neuropsychol. 2015;37(9):988-93. doi: 10.1080/13803395.2015.1073227. J Clin Exp Neuropsychol. 2015. PMID: 26332178 Review.
-
The Genetic Basis of Cognitive Impairment and Dementia in Parkinson's Disease.Front Psychiatry. 2016 May 20;7:89. doi: 10.3389/fpsyt.2016.00089. eCollection 2016. Front Psychiatry. 2016. PMID: 27242557 Free PMC article. Review.
Cited by
-
Effects of Pramipexole Combined with Nerve Growth Factor on Cognitive Impairment and Urinary AD7c-NTP Expression in Patients with Parkinson's Disease.Comput Math Methods Med. 2022 Apr 26;2022:3398732. doi: 10.1155/2022/3398732. eCollection 2022. Comput Math Methods Med. 2022. Retraction in: Comput Math Methods Med. 2023 Jun 28;2023:9787324. doi: 10.1155/2023/9787324. PMID: 35516456 Free PMC article. Retracted.
-
Recipient Reaction and Composition of Autologous Sural Nerve Tissue Grafts into the Human Brain.J Clin Med. 2023 Sep 22;12(19):6121. doi: 10.3390/jcm12196121. J Clin Med. 2023. PMID: 37834764 Free PMC article.
-
Behavioral analysis of motor and non-motor impairment in rodent models of Parkinson's disease.Front Aging Neurosci. 2024 Dec 23;16:1464706. doi: 10.3389/fnagi.2024.1464706. eCollection 2024. Front Aging Neurosci. 2024. PMID: 39763579 Free PMC article. Review.
-
Spontaneous Object Exploration in a Recessive Gene Knockout Model of Parkinson's Disease: Development and Progression of Object Recognition Memory Deficits in Male Pink1-/- Rats.Front Behav Neurosci. 2022 Dec 6;16:951268. doi: 10.3389/fnbeh.2022.951268. eCollection 2022. Front Behav Neurosci. 2022. PMID: 36560930 Free PMC article.
-
Gene Panel Sequencing Analysis Revealed a Strong Contribution of Rare Coding Variants to the Risk of Parkinson's Disease in Sporadic Moroccan Patients.J Mol Neurosci. 2023 Jun;73(6):391-402. doi: 10.1007/s12031-023-02128-9. Epub 2023 May 31. J Mol Neurosci. 2023. PMID: 37256495
References
-
- Winter Y., von Campenhausen S., Arend M., Longo K., Boetzel K., Eggert K., Oertel W.H., Dodel R., Barone P. Health-related quality of life and its determinants in Parkinson’s disease: Results of an Italian cohort study. Parkinsonism Relat. Disord. 2011;17:265–269. doi: 10.1016/j.parkreldis.2011.01.003. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous